Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Immune response following intraocular delivery of recombinant viral vectors

Gene Therapy volume 10, pages 977–982 (2003)Cite this article

Abstract

There has been significant progress in the last few years in demonstrating the utility of recombinant viral vectors in treating a variety of ocular diseases. The field has moved beyond ‘proof-of-principle’ and, in fact, has entered the phase where some of these vectors/paradigms are being or soon will be evaluated in human clinical trials. For this reason and also, to increase the understanding of immunological effects of transgenes/viral vectors on the eye, it is important to summarize what is known about these effects. Here, the biology of and immune responses to intraocular injection of three different recombinant viral vectors – adenovirus, adeno-associated virus (AAV), and lentivirus – are summarized. Perhaps, in part because of the unique immunological environment of the eye, the immunological effects of these viruses appear to be fairly benign. Nevertheless, a significant cell-mediated immune response can develop after intraocular administration of adenovirus. The magnitude of this response is affected by the nature of the intraocular compartment to which this virus is administered. Neither AAV nor lentivirus, however, elicit a cell-mediated response and are thus promising vectors for treatment of chronic ocular (retinal) diseases.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Chowers I et al. Gene transfer by viral vectors into blood vessels in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 2001; 85: 991–995.

    CAS  Google Scholar 

  2. Liu X et al. Herpes simplex virus mediated gene transfer to primate ocular tissues. Exp Eye Res 1999; 69: 385–395.

    Article  CAS  PubMed  Google Scholar 

  3. Sun N, Cassell M, Perlman S . Anterograde, transneuronal transport of Herpes simplex virus type 1 strain H129 in the murine visual system. J Virol 1996; 70: 5405–5413.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Haeseleer F, Imanashi Y, Saperstein D, Palczewski K . Gene transfer mediated by recombinant baculovirus into mouse eye. Invest Ophthalmol Vis Sci 2001; 42: 3294–3300.

    CAS  PubMed  Google Scholar 

  5. Bennett J et al. Adenovirus vector-mediated in vivo gene transfer into adult murine retina. Invest Ophthalmol Vis Sci 1994; 35: 2535–2542.

    CAS  PubMed  Google Scholar 

  6. Li T et al. In vivo transfer of a reporter gene to the retina mediated by an adenoviral vector. Invest Ophthalmol Vis Sci 1994; 35: 2543–2549.

    CAS  PubMed  Google Scholar 

  7. Bennett J, Anand V . Recombinant adenovirus and ocular gene therapy. International Retinitis Pigmentosa Association, 1999, http://www.irpa.org/sci-news/topbenne.htm

    Google Scholar 

  8. Budenz D, Bennett J, Alonso L, Maguire A . In vivo gene transfer into murine trabecular meshwork and corneal endothelial cells. Invest Ophthalmol Vis Sci 1995; 36: 2211–2215.

    CAS  PubMed  Google Scholar 

  9. Larkin DF et al. Adenovirus-mediated gene delivery to the corneal endothelium. Transplantation 1996; 61: 363–370.

    Article  CAS  PubMed  Google Scholar 

  10. Fehervari Z et al. Gene transfer to ex vivo stored corneas. Cornea 1997; 16: 459–464.

    Article  CAS  PubMed  Google Scholar 

  11. Bennett J et al. Photoreceptor cell rescue in retinal degeneration (rd) mice by in vivo gene therapy. Nat Med 1996; 2: 649–654.

    Article  CAS  PubMed  Google Scholar 

  12. Peterson WM et al. Enhanced survival of photoreceptors in P23H mutant rhodopsin transgenic rats by adeno-associated virus (AAV)-mediated delivery of neurotrophic genes. Invest Ophthalmol Vis Sci 1998; 39: S1117.

    Google Scholar 

  13. McGee LH et al. Rescue of photoreceptor degeneration in S334ter(4) mutant rhodopsin transgenic rats by adeno-associated virus (AAV)-mediated delivery of basic fibroblast growth factor. Invest Ophthalmol Vis Sci 1999; 40: S936.

    Google Scholar 

  14. Ali R et al. Restoration of photoreceptor ultrastructure and function in retinal degeneration slow mice by gene therapy. Nat Genet 2000; 25: 306–310.

    Article  CAS  PubMed  Google Scholar 

  15. Lau D et al. Retinal degeneration is slowed in transgenic rats by AAV-mediated delivery of FGF-2. Invest Ophthalmol Vis Sci 2000; 41: 3622–3633.

    CAS  PubMed  Google Scholar 

  16. Liang F-Q et al. Long-term protection of retinal structure but not function using rAAV.CNTF in animal models of retinitis pigmentosa. Mol Ther 2001; 4: 461–472.

    Article  CAS  PubMed  Google Scholar 

  17. Sarra G-M et al. Gene replacement therapy in the retinal degeneration slow (rds) mouse: the effect on retinal degeneration following partial transduction of the retina. Hum Mol Genet 2001; 10: 2353–2361.

    Article  CAS  PubMed  Google Scholar 

  18. Auricchio A et al. Inhibition of retinal neovascularization by intraocular viral mediated delivery of anti-angiogenic agents. Mol Ther 2002; 6: 490–494.

    Article  CAS  PubMed  Google Scholar 

  19. McGee SL, Abel H, Hauswirth W, Flannery J . Glial cell line derived neurotrophic factor delays photoreceptor degeneration in a transgenic rat model of retinitis pigmentosa. Mol Ther 2001; 4: 622–629.

    Article  Google Scholar 

  20. Jomary C et al. Rescue of photoreceptor function by AAV-mediated gene transfer in a mouse model of inherited retinal degeneration. Gene Therapy 1997; 4: 683–690.

    Article  CAS  PubMed  Google Scholar 

  21. Ali RR et al. Gene transfer into the mouse retina mediated by an adeno-associated viral vector. Hum Mol Genet 1996; 5: 591–594.

    Article  CAS  PubMed  Google Scholar 

  22. Flannery J et al. Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus. Proc Natl Acad Sci USA 1997; 94: 6916–6921.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Bennett J, Duan D, Engelhardt J, Maguire AM . Real-time non-invasive in vivo assessment of adeno-associated virus-mediated retinal transduction. Invest Ophthalmol Vis Sci 1997; 38: 2857–2863.

    CAS  PubMed  Google Scholar 

  24. Ho T et al. Phenotypic rescue after adeno-associated virus-mediated delivery of 4-sulfatase to the retinal pigment epithelium of feline mucopolysaccharidosis VI. J Gene Med 2002; 4: 613–621.

    Article  CAS  PubMed  Google Scholar 

  25. Acland G et al. Gene therapy restores vision in a canine model of childhood blindness. Nat Genet 2001; 28: 92–95.

    CAS  PubMed  Google Scholar 

  26. Dudus L et al. Persistent transgene product in retina, optic nerve and brain after intraocular injection of rAAV. Vision Res 1999; 39: 2545–2554.

    Article  CAS  PubMed  Google Scholar 

  27. Bennett J, Anand V, Acland GM, Maguire AM . Cross-species comparison of in vivo reporter gene expression after rAAV-mediated retinal transduction. Methods Enzymol 2000; 316: 777–789.

    Article  CAS  PubMed  Google Scholar 

  28. Auricchio A et al. Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. Hum Mol Genet 2001; 10: 3075–3081.

    Article  CAS  PubMed  Google Scholar 

  29. Rabinowitz J et al. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 2002; 76: 791–801.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Streilein J . Immune regulation and the eye: a dangerous compromise. FASEB J 1987; 1: 199–208.

    Article  CAS  PubMed  Google Scholar 

  31. Kosiewicz M, Alard P, Streilein J . Alterations in cytokine production following intraocular injection of soluble protein antigen: impairment in IFN-g and induction of TGF-b and IL-4 production. J Immunol 1998; 161: 5382–5390.

    CAS  PubMed  Google Scholar 

  32. D'Orazio T, Niederkorn J . The nature of antigen in the eye has a profound effect on the cytokine milieu and resultant immune response. Eur J Immunol 1998; 28: 1544–1553.

    Article  CAS  PubMed  Google Scholar 

  33. Jiang LQ, Jorquera M, Streilein JW, Ishioka M . Unconventional rejection of neural retinal allografts implanted into the immunologically privileged site of the eye. Transplantation 1995; 59: 1201–1207.

    Article  CAS  PubMed  Google Scholar 

  34. Wenkel H, Streilein JW . Analysis of immune deviation elicited by antigens injected into the subretinal space. Invest Ophthalmol Vis Sci 1998; 39: 1823–1834.

    CAS  PubMed  Google Scholar 

  35. Wilbanks GA, Streilein JW . Studies on the induction of anterior chamber-associated immune deviation (ACAID). 1. Evidence that an antigen-specific, ACAID-inducing, cell-associated signal exists in the peripheral blood. J Immunol 1991; 146: 2610–2617.

    CAS  PubMed  Google Scholar 

  36. Wilson SE et al. Epidermal growth factor, transforming growth factor alpha, transforming growth factor beta, acidic fibroblast growth factor, basic fibroblast growth factor, and interleukin-1 proteins in the cornea. Exp Eye Res 1994; 59: 63–71.

    Article  CAS  PubMed  Google Scholar 

  37. Khaw PT, Schultz GS, MacKay SL . Detection of transforming growth factor – alpha messenger RNA and protein in human corneal epithelial cells. Invest Ophthalmol Vis Sci 1992; 33: 3302–3306.

    CAS  PubMed  Google Scholar 

  38. Taylor AW, Streilein JW, Cousins SW . Immunoreactive vasoactive intestinal peptide contributes to the immunosuppressive activity of normal aqueous humor. J Immunol 1994; 153: 1080–1086.

    CAS  PubMed  Google Scholar 

  39. Griffith TS et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189.

    Article  CAS  PubMed  Google Scholar 

  40. Shimada K . The complement component and their inactivators in the intraocular fluids of the guinea pig. Invest Ophthalmol Vis Sci 1970; 9: 307–315.

    CAS  Google Scholar 

  41. Bora NS et al. Differential expression in the complement regulatory proteins in the human eye. Invest Ophthalmol Vis Sci 1993; 34: 3579–3584.

    CAS  PubMed  Google Scholar 

  42. Hoffman LM, Maguire AM, Bennett J . Cell-mediated immune response and stability of intraocular transgene expression after adenovirus-mediated delivery. Invest Ophthalmol Vis Sci 1997; 38: 2224–2233.

    CAS  PubMed  Google Scholar 

  43. Reichel M et al. Immune responses limit adenovirally mediated gene expression in the adult mouse eye. Gene Therapy 1998; 5: 1038–1046.

    Article  CAS  PubMed  Google Scholar 

  44. Maguire AM et al. Adenovirus-mediated gene transfer to canine retinal photoreceptors: effects of inflammation. Invest Ophthalmol Vis Sci 1995; 36: S777.

    Google Scholar 

  45. Judge TA et al. The in vivo mechanism of action of CTLA4Ig. J Immunol 1996; 156: 2294–2299.

    CAS  PubMed  Google Scholar 

  46. Ali RR et al. Co-injection of adenovirus expressing CTLA4-Ig prolongs adenovirally mediated lacZ reporter gene expression in the mouse retina. Gene Therapy 1998; 5: 1561–1565.

    Article  CAS  PubMed  Google Scholar 

  47. Di Polo A et al. Prolonged delivery of brain-derived neurotrophic factor by adenovirus-infected Muller cells temporarily rescues injured retinal ganglion cells. Proc Natl Acad Sci USA 1998; 95: 3978–3983.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Jooss K, Yang Y, Fisher KJ, Wilson JM . Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol 1998; 72: 4212–4223.

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Anand V et al. A deviant immune response to viral proteins and transgene product is generated on subretinal administration of adenovirus and adeno-associated virus. Mol Ther 2002; 5: 125–132.

    Article  CAS  PubMed  Google Scholar 

  50. Bennett J, Pakola S, Zeng Y, Maguire AM . Humoral antibody response after administration of E1-deleted adenoviruses: immune privilege of the subretinal space. Human Gene Ther 1996; 7: 1763–1769.

    Article  CAS  Google Scholar 

  51. Hurwitz M et al. Suicide gene therapy for treatment of retinoblastoma in a murine model. Human Gene Ther 1999; 10: 441–448.

    Article  CAS  Google Scholar 

  52. Rasmussen H et al. Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). Hum Gene Ther 2001; 12: 2029–2032.

    CAS  PubMed  Google Scholar 

  53. Blacklow NR et al. Epidemiology of adeno-associated virus infection in a nursery population. Am J Epidemiol 1968; 88: 368–378.

    Article  CAS  PubMed  Google Scholar 

  54. Samulski RJ, Chang L-S, Shenk T . Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol 1989; 63: 3822–3828.

    CAS  PubMed  PubMed Central  Google Scholar 

  55. Li X, D'Orazio L, Niederkorn J . Role of Th1 and Th2 cells in anterior chamber-associated immune deviation. Immunology 1996; 89: 34–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Anand V, Maguire AM, Bennett J . High levels of transgene expression after readministration of adeno-associated virus to the subretinal space. Invest Ophthalmol Vis Sci 1999; 40: S592.

    Google Scholar 

  57. Bennett J et al. Recombinant adeno-associated virus-mediated gene transfer to the monkey retina. Proc Natl Acad Sci USA 1999; 96: 9920–9925.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Karakousis P et al. Favorable immune response following subretinal administration of lentivirus, submitted.

Download references

Acknowledgements

Research support from NIH U10 013729, RO1s EY10820 and EY12156, the Foundation Fighting Blindness, the Paul and Evanina Mackall Trust, the Lois Pope LIFE Foundation, the William and Mary Greve International Research Scholar Award (Research to Prevent Blindness, Inc.), the Ruth and Ann Milton Steinbach Fund, and the FM Kirby Foundation is gratefully acknowledged.

Author information

Authors and Affiliations

  1. FM Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia, PA, USA

    J Bennett

Authors
  1. J Bennett
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bennett, J. Immune response following intraocular delivery of recombinant viral vectors. Gene Ther 10, 977–982 (2003). https://doi.org/10.1038/sj.gt.3302030

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3302030

Keywords

This article is cited by

Search

Advanced search

Quick links